Pfizer Advances Daily Weight Loss Pill Amid FDA Rejection of Novo's Insulin

The FDA's decision impacts Novo Nordisk's weekly insulin, while Pfizer's new GLP-1 pill shows promise in weight management.

Pfizer is developing a once-daily weight loss pill, danuglipron, aiming to compete in the GLP-1 space.
The FDA rejected Novo Nordisk's application for its once-weekly insulin icodec, citing concerns over manufacturing and safety.
The FTC report highlights that pharmacy benefit managers are driving up drug prices, leading to planned lawsuits.
Eli Lilly's diabetes and weight loss drugs are outperforming Novo Nordisk's medications in recent studies.
Eli Lilly is set to acquire Morphic for $3.2 billion, expanding its portfolio in inflammatory bowel disease treatments.